<< Back to News

System Formulary Update
Nivolumab/Hyaluronidase-nvhy (Opdivo Qvantig)
May 21, 2025

Situation: Nivolumab/hyaluronidase-nvhy (Opdivo Qvantig) SDV for subcutaneous injection was approved for addition to the UNC Health System Formulary at the System Pharmacy and Therapeutics Committee meeting.

Background: The following medication was reviewed: Nivolumab/hyaluronidase-nvhy (Opdivo Qvantig) SDV for subcutaneous injection 

Assessment/Recommendation: System P&T voted to include the following products to the UNC Health Medication Formulary with restrictions: Nivolumab 600 mg- Hyaluronidase-nvhy 10,000 unit/5 mL subcutaneous solution

• Restricted to outpatient, clinic encounters only (i.e., no inpatient use)
• Orders must be signed by a Hematology/Oncology Attending Physician 

Formulary/Epic Changes will Go-Live on Tuesday, June 24th